Document resource
Lung cancer mortality has declined in recent years after decades of limited progress; however, it remains the leading cause of cancer-related deaths. This encouraging trend is partly attributed to earlier detection through the implementation of lung cancer screening programmes and the increasing identification of incidental lung nodules. These developments underscore the growing need to advance diagnostic capabilities and technologies for peripheral pulmonary lesions (PPLs).1–3 Significant investments and technological innovations in this area have led to the development of various diagnostic tools, including robotic bronchoscopy and real-time imaging techniques. These approaches aim to improve diagnostic yield via bronchoscopy while reducing complication rates, moving away from traditional transthoracic biopsy methods.4 As a result, these efforts have garnered substantial interest from clinicians, researchers and industry stakeholders.